Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB versus EXKIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB versus EXKIVITY.
BOSUTINIB vs EXKIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that inhibits the BCR-ABL kinase, including many imatinib-resistant mutations, and Src family kinases.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
400 mg orally once daily with food.
150 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 33 hours (range 22-60 hr) after oral administration, supporting once-daily dosing.
Clinical Note
moderateBosutinib + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Bosutinib."
Clinical Note
moderateBosutinib + Digitoxin
"Bosutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBosutinib + Deslanoside
"Bosutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBosutinib + Acetyldigitoxin
"Bosutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Primarily fecal (approx. 68% as unchanged drug and metabolites) and renal (approx. 25%, with <0.2% as unchanged drug in urine).
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor